Rising incidence of radiation pneumonitis after adjuvant durvalumab in NSCLC patients treated with concurrent chemoradiotherapy
Adjuvant durvalumab significantly increased the incidence of grade ≥2 RP in this real-world cohort of NSCLC patients. Patients receiving adjuvant durvalumab remain prone to develop grade ≥2 RP longer after completing CRT compared to patients treated with CRT only.
Authors
- Johannes A. Langendijk (ORCID: https://orcid.org/0000-0003-1083-372X)
- Gea Douma
- O. Chouvalova
- Robin Wijsman (ORCID: https://orcid.org/0000-0001-5139-0908)
- Jan F. Ubbels
- Lisanne V. van Dijk (ORCID: https://orcid.org/0000-0002-9515-5616)
- Anne G.H. Niezink (ORCID: https://orcid.org/0009-0009-2860-8767)
- Marleen Woltman-van Iersel
- T. Jeroen N. Hiltermann (ORCID: https://orcid.org/0000-0002-0665-2160)
- Rutger H. Stoffers (ORCID: https://orcid.org/0009-0000-1052-0999)
- Lucie B.M. Hijmering-Kappelle
- S.M. de Hosson
- John W.G. van Putten
- Friso T. Zandberg
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- Treant Zorggroep (NL)
- Martini Ziekenhuis (NL)
- Wilhelmina Children's Hospital (NL)
Publication Details
- Journal
- Acta Oncologica
- Published
- 2025-02-13
- DOI
- https://doi.org/10.2340/1651-226x.2025.42384
- Citations
- 3
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.56